NewsBenzingaEikon Therapeutics、一次治療のステージ4非小細胞肺がんにおいて、EIK1001とペムブロリズマブおよび化学療法の併用が、標準治療との併用で持続的な効果を示し、外来での全身投与を支持する忍容性プロファイルを示したと発表 Eikon Therapeutics、一次治療のステージ4非小細胞肺がんにおいて、EIK1001とペムブロリズマブおよび化学療法の併用が、標準治療との併用で持続的な効果を示し、外来での全身投与を支持する忍容性プロファイルを示したと発表 Benzinga 2026.10.26 10:13 (GMT+0) Open on Benzinga Other news Bitcoin, XRP, Dogecoin Slide, Ethereum Steady as ‘Extreme Fear’ Persists: Analyst Says ‘Selling Hasn’t Stopped Yet’ as Whales Offload BTC United Airlines Says Tech Glitch ‘Has Been Resolved’ After Delaying Departures Days After FAA Outage Chaos Jana Partners Cashes Out of One Data Center Stock for Another and Buys Trash Company Stock in Q3 $100 Invested In Vanguard Russell 1000 Growth ETF 15 Years Ago Would Be Worth This Much Today Seth Klarman’s Baupost Group Takes New Position in Honeywell Aerospace in Q3 Here’s How Much You Would Have Made Owning Advanced Micro Devices Stock In The Last 15 Years
Bitcoin, XRP, Dogecoin Slide, Ethereum Steady as ‘Extreme Fear’ Persists: Analyst Says ‘Selling Hasn’t Stopped Yet’ as Whales Offload BTC
United Airlines Says Tech Glitch ‘Has Been Resolved’ After Delaying Departures Days After FAA Outage Chaos